Systemic Vasculitis
15
3
3
5
Key Insights
Highlights
Success Rate
63% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
20.0%
3 terminated out of 15 trials
62.5%
-24.1% vs benchmark
27%
4 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 5 completed trials
Clinical Trials (15)
Acquired Immunodeficiency in ANCA Associated Vasculitis
Vasculitis Pregnancy Registry
Circulating B-cell, Drug and Anti-drug Antibodies Monitoring in Patients Treated With Rituximab for Autoimmune Disorders
Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases
Rare AutoImmune SElf-management Programme Development
Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease
COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases
Resistance Exercise in Rheumatic Disease
Rituximab Plus Corticosteroids in Non-infectious Active Mixed Cryoglobulinemia Vasculitis
Study of Refractory and/or Relapsing TAkayasu aRTeritis
Journey of Patients With Vasculitis From First Symptom to Diagnosis
GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases
Magnetic Resonance Angiography vs Ultrasonography in Systemic Large vEssel vasculitiS
Impact of Vasculitis on Employment and Income
Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases